Exelixis, Inc.

Healthcare · Biotechnology

Overall research band Exceptional

Quality Exceptional

Valuation Exceptional

Balance sheet Exceptional

Market confirmation Above average

One-minute company read

What this report can tell you now

What the company does

Exelixis, Inc. is a biotechnology company based in Alameda, California, focused on developing and marketing novel cancer therapies in the United States. Its main products include CABOMETYX tablets for advanced renal cell carcinoma and COMETRIQ capsules for progressive and metastatic medullary thyroid cancer, both derived from the compound cabozantinib, which inhibits multiple tyrosine kinases. The company also offers COTELLIC, an MEK inhibitor for advanced melanoma, and MINNEBRO, a mineralocorticoid receptor blocker for hypertension in Japan. Exelixis generates revenue primarily through the sale of these therapeutics and maintains research and licensing partnerships with various pharmaceutical and biotechnology companies. Its pipeline includes investigational drugs such as XL092, XB002, and XL102, targeting a range of advanced cancers.

The current research profile is Exceptional Compounder, with strong market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC35.6%Model input; read with the evidence status and period context.

Operating margin37.6%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years12.8%Model input; read with the evidence status and period context.

FCF margin36.4%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.